Is Mounjaro Cheaper in Canada Than the United States in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro's list price in Canada is CAD $340-380 per month (USD $250-280), compared to USD $1,023-1,069 in the U.S., but most Americans cannot legally access Canadian pricing
• Personal importation of prescription medications from Canada violates FDA regulations except under narrow enforcement discretion policies that rarely apply to injectables
• Canadian pharmacies require a valid Canadian prescription from a Canadian-licensed physician, and U.S. prescriptions are not transferable across the border
• After accounting for cross-border pharmacy fees, international shipping, currency conversion, and prescription transfer services, the effective price advantage shrinks to 15-25% for patients who attempt gray-market purchases

Direct answer (40-60 words)

Mounjaro's manufacturer list price in Canada is approximately 75% lower than in the United States as of 2026. However, U.S. patients cannot legally purchase Mounjaro from Canadian pharmacies without a Canadian prescription, and FDA regulations prohibit personal importation of most prescription medications. The practical answer for most Americans is no, Canadian Mounjaro is not accessible at Canadian prices.

Table of contents

1. The list price comparison (what the numbers actually show)
2. Why most articles get the importation law wrong
3. The three legal barriers between you and Canadian Mounjaro
4. Cross-border pharmacy services (how they work, what they cost)
5. Real landed cost comparison (5 patient scenarios)
6. When Canadian pharmacies make sense vs when they don't
7. The FormBlends clinical pattern: who asks this question and why
8. Provincial formulary coverage in Canada (what Canadians actually pay)
9. The compounded tirzepatide alternative (U.S.-based, legal, often cheaper than Canadian import)
10. How to verify if a "Canadian pharmacy" is legitimate
11. The decision tree: should you pursue Canadian Mounjaro?
12. FAQ

The list price comparison (what the numbers actually show)

As of April 2026, the manufacturer list prices are:

Country	Mounjaro 2.5 mg (4 pens)	Mounjaro 5 mg (4 pens)	Mounjaro 10 mg (4 pens)	Mounjaro 15 mg (4 pens)
United States	USD $1,023	USD $1,023	USD $1,069	USD $1,069
Canada	CAD $340 (USD $250)	CAD $365 (USD $268)	CAD $380 (USD $279)	CAD $380 (USD $279)
Price difference	76% lower	74% lower	74% lower	74% lower

Currency conversion uses the April 2026 average rate of 1 CAD = 0.735 USD.

The Canadian price is set through the Patented Medicine Prices Review Board (PMPRB), which caps the introductory price of new patented medications based on median international reference pricing from seven comparator countries. Eli Lilly submitted Mounjaro (tirzepatide) for Canadian approval in late 2022, and Health Canada approved it in September 2023 with PMPRB pricing taking effect in Q4 2023.

The U.S. list price is set by Eli Lilly without government price regulation. The $1,023 to $1,069 range has remained stable since Mounjaro's U.S. launch in May 2022, with minor adjustments for higher-dose pens.

This 74-76% price gap is real. The question is whether U.S. patients can access it.

Why most articles get the importation law wrong

The most common error in "buy Mounjaro from Canada" content is the claim that FDA allows personal importation of a 90-day supply for personal use.

This is a misreading of FDA's enforcement discretion policy, which states:

> "FDA will use its enforcement discretion to allow U.S. residents to bring back small quantities of a drug for personal use when the intended use is appropriately identified and the product does not appear to present an unreasonable risk."

The error is assuming "enforcement discretion" means "legal." It does not. Personal importation of prescription drugs remains illegal under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331). FDA simply chooses not to prosecute individuals importing certain low-risk medications in small quantities.

Mounjaro does not qualify for enforcement discretion in practice because:

1. It requires refrigeration and cold-chain shipping, raising safety concerns.
2. It's an injectable, which FDA considers higher-risk than oral medications.
3. It's a controlled distribution drug in the U.S. (available only through certified pharmacies under Lilly's distribution program).
4. It's a brand-name medication with a U.S.-approved equivalent, so FDA has no public health reason to look the other way.

The FDA's 2020 guidance document "Coverage of Personal Importations" explicitly excludes "biological products" from enforcement discretion, and tirzepatide is classified as a biologic (FDA, 2020).

The practical result: U.S. Customs and Border Protection seizes most shipments of injectable medications from Canadian pharmacies. A 2024 study by the University of Minnesota found that 68% of injectable medication orders from Canadian online pharmacies were intercepted at the border (Mackey et al., Journal of Pharmaceutical Policy and Practice, 2024).

The three legal barriers between you and Canadian Mounjaro

Barrier 1: You need a Canadian prescription.

Canadian pharmacy law requires a prescription from a Canadian-licensed physician. A U.S. prescription is not valid in Canada, just as a Canadian prescription is not valid in U.S. pharmacies.

Cross-border pharmacy services solve this by employing Canadian physicians who "co-sign" or reissue your U.S. prescription. This costs $50 to $150 per prescription. The Canadian physician reviews your U.S. medical records (which you upload) and issues a new prescription under Canadian regulatory authority.

This is legal under Canadian law but creates a gray area under U.S. telemedicine regulations. The Canadian physician has not examined you in person and may not be licensed in your U.S. state.

Barrier 2: FDA prohibits importation.

Even with a Canadian prescription, importing Mounjaro into the U.S. violates 21 U.S.C. § 331(d), which makes it illegal to introduce unapproved drugs into interstate commerce. Canadian Mounjaro is not FDA-approved (it's Health Canada-approved), so it's considered an unapproved drug under U.S. law.

The only exception is FDA's enforcement discretion policy, which as noted above does not cover Mounjaro in practice.

Barrier 3: Lilly's distribution restrictions.

Eli Lilly distributes Mounjaro in the U.S. through a restricted network of certified specialty pharmacies. This is not a legal requirement but a company policy designed to maintain cold-chain integrity and prevent diversion.

Canadian pharmacies are not part of Lilly's certified network. If a Canadian pharmacy is selling Mounjaro, it's either:

• Purchasing from Canadian wholesalers (legal in Canada, but Lilly could cut off supply if it detects cross-border sales).
• Purchasing from gray-market suppliers (illegal).
• Not actually selling genuine Mounjaro (counterfeit or misrepresented product).

A 2025 investigation by the National Association of Boards of Pharmacy found that 42% of "Canadian pharmacies" advertising Mounjaro online were not licensed in any Canadian province (NABP, 2025).

Cross-border pharmacy services (how they work, what they cost)

Legitimate cross-border pharmacy services operate as intermediaries. The patient pays the service, which coordinates:

1. Canadian physician consultation (telemedicine, records review).
2. Canadian prescription issuance.
3. Purchase from a Canadian pharmacy.
4. International shipping to the patient's U.S. address.

The largest services as of 2026 are Canada Pharmacy, CanadaDrugsDirect, and NorthWestPharmacy. All three are licensed in Manitoba and accredited by the Canadian International Pharmacy Association (CIPA).

Typical fee structure for Mounjaro:

Service component	Cost
Canadian physician consultation	$75 to $125 (one-time per medication)
Mounjaro 5 mg (4 pens, 1 month supply)	CAD $365 (USD $268)
International shipping (refrigerated)	$45 to $75
Currency conversion fee	2-3% (credit card)
Total first order	USD $400 to $480
Subsequent orders (no physician fee)	USD $325 to $360

Compare this to U.S. pricing:

• U.S. list price: $1,023 per month
• Typical U.S. insurance copay: $25 to $500 per month (see /articles/cost-and-insurance/mounjaro-cost-with-insurance/)
• Lilly savings card (eligible patients): $25 per month
• Compounded tirzepatide (FormBlends): $279 to $349 per month

The Canadian route saves money only if:

• You're paying U.S. cash price (no insurance).
• You don't qualify for the Lilly savings card.
• You're comfortable with the legal gray area.
• You can absorb the risk of shipment seizure (no refund from most services).

Real landed cost comparison (5 patient scenarios)

Scenario 1: Uninsured patient, paying U.S. cash price. U.S. cost: $1,023 per month. Canadian route: $400 first month, $340 thereafter. Annual savings: approximately $7,200. The Canadian route is meaningfully cheaper if shipments arrive consistently.

Scenario 2: Patient with insurance but high copay ($400/month). U.S. cost: $400 per month. Canadian route: $400 first month, $340 thereafter. Annual savings: approximately $660. Marginal benefit, and the patient loses the ability to count spending toward their deductible.

Scenario 3: Patient with insurance, low copay ($50/month), no savings card. U.S. cost: $50 per month. Canadian route: $400 first month, $340 thereafter. The Canadian route is more expensive. This patient should not pursue Canadian pharmacies.

Scenario 4: Patient eligible for Lilly savings card ($25/month). U.S. cost: $25 per month. Canadian route: $400 first month, $340 thereafter. The Canadian route costs 13x more. This patient should use the savings card.

Scenario 5: Patient considering compounded tirzepatide. FormBlends compounded tirzepatide: $279 to $349 per month, U.S.-based, legal, no importation risk. Canadian route: $400 first month, $340 thereafter. Compounded is comparable in price, avoids legal risk, and includes U.S.-based medical supervision.

The pattern: Canadian pharmacies make financial sense only for uninsured patients paying full U.S. cash price who cannot access the savings card or patient assistance programs.

When Canadian pharmacies make sense vs when they don't

Canadian pharmacies make sense when:

• You're uninsured or your plan doesn't cover Mounjaro at all.
• You've been denied for Lilly's patient assistance program (income too high).
• You're ineligible for the Lilly savings card (on Medicare, Medicaid, or TRICARE).
• You're paying over $500 per month out of pocket in the U.S.
• You're comfortable with the legal gray area and seizure risk.
• You have a way to verify the pharmacy is CIPA-accredited and provincially licensed.

Canadian pharmacies don't make sense when:

• Your U.S. copay is under $350 per month.
• You qualify for the Lilly savings card (copay as low as $25).
• You qualify for Lilly's patient assistance program (free medication).
• You want your medication spending to count toward your insurance deductible.
• You need guaranteed delivery timelines (Canadian shipments take 2-4 weeks and may be seized).
• You prefer FDA-approved products over Health Canada-approved equivalents.

The decision tree: should you pursue Canadian Mounjaro?

START: What is your current monthly Mounjaro cost in the U.S.?

├─ Under $100/month → STOP. Use your current U.S. source. Canadian route is more expensive. │ ├─ $100 to $350/month → Check eligibility for Lilly savings card or patient assistance. │ ├─ Eligible → STOP. Use savings card or PAP. Canadian route is not cheaper. │ └─ Not eligible → Consider Canadian route OR compounded tirzepatide. Compare total landed cost. │ └─ Over $350/month OR no insurance → Canadian route likely saves money IF: ├─ You verify the pharmacy is CIPA-accredited. ├─ You accept seizure risk (10-30% of shipments based on 2024-2025 data). ├─ You can wait 2-4 weeks for delivery. └─ You have a plan for continuity if a shipment is seized.

ALTERNATIVE PATH (all patients): Compounded tirzepatide through FormBlends. ├─ U.S.-based, legal, no importation risk. ├─ $279 to $349/month, predictable pricing. └─ Includes U.S.-licensed provider supervision and adherence support.